The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...

Here & Now’s Peter O’Dowd spoke with Sarah Zhang, a reporter for The Atlantic, about how people are searching the web and using the app Telegram to buy next-generation GLP-3 drugs not yet approved by ...